Rheumatology

Wesley Mizutani, MD, discusses California's SB 496 legislation, which addresses the crucial role of biomarkers in guiding optimal drug selection to improve overall healthcare outcomes.

In a new study, 31.9% of individuals with osteoporosis had depressive symptoms and 10% had probable depression.

A retrospective cohort analysis suggests the monoclonal antibody may help patients with SLE reduce their reliance on oral corticosteroids over 1 year after initiating treatment.

The PETRA questionnaire proves valuable in assessing the transition readiness of juvenile idiopathic arthritis patients into adult care, with a focus on self-management skills.

In this discussion, experts focus on emerging treatment options for gout and share tips for monitoring and managing gout in patients with comorbid conditions.

The progression toward more targeted, disease-modifying options for the historically difficult rheumatic disease made more headway in 2023.

Philip J. Mease, MD, highlights the potential of blood biomarkers to assist with diagnosing fibromyalgia, as well as other imaging modalities.

Philip J. Mease, MD, discusses treatment selection in fibromyalgia, highlighting combination therapy as well as the importance of a holistic approach to care.

Throughout 2023, interest in the application of CAR-T and other cell therapies to autoimmune disease skyrocketed, with a multitude of clinical trials being initiated by various companies.

Philip J. Mease, MD, discusses treatment selection in fibromyalgia, highlighting combination therapy as well as the importance of a holistic approach to care.

An expert rheumatologist reviews the efficacy and safety of the 3 FDA-approved therapies for treating fibromyalgia—pregabalin, duloxetine, and milnacipran.

Expert rheumatologists discuss current treatment options for lupus nephritis and emerging therapies with newer mechanisms of action.

Philip J. Mease, MD, comments on the importance of education about fibromyalgia, especially regarding the stigma and the psychological impact of the disease.

Philip J. Mease, MD, provides an overview of fibromyalgia as a primary disorder of central pain processing and modulation.

Dr Daniel J. Clauw shares clinical pearls for the treatment of patients with fibromyalgia and comments on future developments in the pipeline for disease management.

Daniel J. Clauw, MD, shares his approach to selecting FDA approved therapeutic agents for fibromyalgia treatment and his clinical treatment strategy when first-line pharmacological therapy fails.

We kick off our annual recap series with some reflections from our expert advisory board, on topics ranging from AI and cell therapies, to semaglutide and RSV vaccines.

In a new study, decreased plasma EGR1 protein levels and patients with fibromyalgia had a statistically significant relationship.

Resilience of participants with fibromyalgia had a stronger protective association among participants with average null or mild pain than with moderate or severe pain.

Dr Daniel J. Clauw provides an overview of pharmacologic and nonpharmacologic therapeutic approaches for the management of fibromyalgia and comments on challenges and unmet needs for patients.

Daniel J. Clauw, MD, describes the role the brain and CNS play in controlling the setting of nociplastic pain in patients with fibromyalgia and highlights increased patient sensitivity to sensory stimuli.

During this interview segment, Dr. Deodhar described his presentation at the ACR 2023 convergence on longitudinal data regarding bimekizumab for patients with this condition.

In a new study, patients with psoriasis had a 39.46% prevalence of being overweight and 37.41% prevalence of obesity—83.56% patients also dismissed the importance of having healthy balanced eating habits.

A new study suggests vitamin D2 supplementation on patients with psoriasis is superior to vitamin D3 supplementation, but there was no significant difference in heterogeneity.

The 2 groups—the active control group who received smartphone notifications about general health advice and the intervention group who receive notifications on adherence-targeted information—did not have significant differences in serum urate levels.

In a recent study, participants had highest gout flare rates when serum urate levels were > 10 mg/dL and the lowest gout flare when levels were < 3.9 mg/dL.

At the follow-up with a study sample of 16.7 million patients, 6.9% of gout patients had chronic opioid use (n = 28,948) while 3.8% of the non-gout patients did.

This data represented the first-ever research presented at ACR on both fractures and calcium pyrophosphate deposition disease.

During this interview segment, Dr. Alevizos discussed some of the implications of his team’s findings regarding dazodalibep.